Upstream Bio, Inc. is trading at $7.26 (10.2% down) following a sharp intraday selloff, despite no new confirmed company-specific news or SEC filings hitting the tape.
- The move follows recent volatility tied to prior coverage of clinical trial data and gene-therapy related sentiment.
- Market observers suggest traders are unwinding bullish positions in a generally flat broader market today.